MedScape is reporting that the North American Menopause Society (NAMS) has updated its guidelines on postmenopausal hormone therapy (HT) and issued a position statement published in the July/August issue of Menopause. Recent data suggest that the benefit-risk ratio for HT is favorable near menopause but decreases with aging and time since menopause in previously untreated women.

My Take?